PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications

Abstract Pancreatic cancer is a highly lethal disease with a poor prognosis, and existing therapies offer only limited effectiveness. Mutation gene sequencing has shown several gene associations that may account for its carcinogenesis, revealing a promising research direction. Poly (ADP-ribose) poly...

Full description

Bibliographic Details
Main Authors: Heng Zhu, Miaoyan Wei, Jin Xu, Jie Hua, Chen Liang, Qingcai Meng, Yiyin Zhang, Jiang Liu, Bo Zhang, Xianjun Yu, Si Shi
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Molecular Cancer
Subjects:
PARP inhibitor
Pancreatic cancer
BRCA
Synthetic lethality
Homologous recombination repair
Chemotherapy resistance
Online Access:http://link.springer.com/article/10.1186/s12943-020-01167-9

Internet

http://link.springer.com/article/10.1186/s12943-020-01167-9

Similar Items